Authors: Sharon Salt, Future Science Group
In a recently published study, researchers employed a randomized, double-blind, placebo-controlled Phase I/II clinical trial to assess the safety and virologic effect of a therapeutic HIV vaccine. The study design included HIV-infected individuals who began antiretroviral therapy (ART) during acute or early infection.
Although ART has provided tremendous benefits for prolonging lifespans of individuals infected with HIV, complete eradication has not been possible. Thus, therapeutic vaccination has emerged as a potential strategy to boost host immune responses in the absence of ART.